Hemagglutinating and binding properties of botulinum C2 toxin.
To characterize the binding substance(s) for botulinum C2 toxin, the hemagglutinating activity of component II of botulinum C2 toxin (C2II) was studied by hemagglutination and hemagglutination inhibition. Human and animal erythrocytes were agglutinated by trypsinized C2II much more strongly than by untreated C2II. Trypsinized C2II agglutinated neuraminidase-treated erythrocytes more strongly than intact, trypsin- and pronase-treated ones. On the other hand, trypsin- and pronase-treated erythrocytes were more weakly hemolyzed by trypsinized C2II than intact and neuraminidase-treated ones, and trypsinized C2II showed both hemagglutinating and hemolytic activities to these erythrocytes. Hemagglutination of trypsin-treated human type B erythrocytes was inhibited by galactose, N-acetylgalactosamine, N-acetylglucosamine, L-fucose and mannose. Thyroglobulin and bovine salivary mucin were much stronger inhibitors. From these findings, the binding substance(s) for botulinum C2 toxin on erythrocytes is(are) suggested to be glycoprotein(s).
Sugii
S
S
Department of Serology and Immunology, School of Medical Technology, Kitasato University, Kanagawa, Japan.
Kozaki
S
S
D000116:Acetylgalactosamine / Q000494:pharmacology; D000117:Acetylglucosamine / Q000494:pharmacology; D000818:Animals; D001905:Botulinum Toxins / Q000378:metabolism / Q000494:pharmacology*; D005643:Fucose / Q000494:pharmacology; D005690:Galactose / Q000494:pharmacology; D006384:Hemagglutination; D006385:Hemagglutination Inhibition Tests; D006386:Hemagglutination Tests; D006461:Hemolysis; D006801:Humans; D008358:Mannose / Q000494:pharmacology; D009439:Neuraminidase / Q000494:pharmacology; D011402:Pronase / Q000494:pharmacology; D014357:Trypsin / Q000494:pharmacology
D005643:Fucose; D009439:Neuraminidase; D014357:Trypsin; D011402:Pronase; D001905:Botulinum Toxins; D000116:Acetylgalactosamine; D008358:Mannose; D000117:Acetylglucosamine; D005690:Galactose